Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00269152
Status:
COMPLETED
Last Update Posted:
2015-08-18
First Post:
2005-12-21
Brief Title:
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter open-label two-arm randomized parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin Arm A or carboplatin Arm B as adjuvant combination-chemotherapy in participants with completely resected stage Ib or IIaIIb non-small cell lung cancer NSCLC
A two-stage design will be employed independently for both treatment arms with the possibility of stopping each treatment early for lack of feasibility
A two-stage design will be employed independently for both treatment arms with the possibility of stopping each treatment early for lack of feasibility
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-SB-S089 | OTHER | Eli Lilly and Company | None |